[go: up one dir, main page]

PL2844253T3 - Trytokwalina do stosowania w leczeniu mukowiscydozy - Google Patents

Trytokwalina do stosowania w leczeniu mukowiscydozy

Info

Publication number
PL2844253T3
PL2844253T3 PL13718559.1T PL13718559T PL2844253T3 PL 2844253 T3 PL2844253 T3 PL 2844253T3 PL 13718559 T PL13718559 T PL 13718559T PL 2844253 T3 PL2844253 T3 PL 2844253T3
Authority
PL
Poland
Prior art keywords
tritoqualine
treatment
cystic fibrosis
cystic
fibrosis
Prior art date
Application number
PL13718559.1T
Other languages
English (en)
Inventor
Dominique Costantini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2844253T3 publication Critical patent/PL2844253T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13718559.1T 2012-04-30 2013-04-19 Trytokwalina do stosowania w leczeniu mukowiscydozy PL2844253T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305487.6A EP2659890A1 (en) 2012-04-30 2012-04-30 Methods and compositions for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
PL2844253T3 true PL2844253T3 (pl) 2016-09-30

Family

ID=48184183

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13718559.1T PL2844253T3 (pl) 2012-04-30 2013-04-19 Trytokwalina do stosowania w leczeniu mukowiscydozy

Country Status (14)

Country Link
US (1) US9301955B2 (pl)
EP (2) EP2659890A1 (pl)
CA (1) CA2871815C (pl)
CY (1) CY1117620T1 (pl)
DK (1) DK2844253T3 (pl)
ES (1) ES2569391T3 (pl)
HR (1) HRP20160328T1 (pl)
HU (1) HUE027353T2 (pl)
IL (1) IL235358B (pl)
PL (1) PL2844253T3 (pl)
RS (1) RS54733B1 (pl)
SI (1) SI2844253T1 (pl)
SM (1) SMT201600102B (pl)
WO (1) WO2013164204A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006332726B2 (en) 2005-12-28 2012-12-13 Vertex Pharmaceuticals Incorporated. Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
FR2990859B1 (fr) * 2012-05-24 2014-05-23 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
BR112016010403A2 (pt) * 2013-11-12 2017-08-08 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
FR3015977B1 (fr) * 2013-12-30 2016-01-01 Patrice Binay Chlorhydrate de tritoqualine sous forme cristallisee et procede d'obtention
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
FR3048883B1 (fr) * 2016-03-18 2020-10-02 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
FR3109524B1 (fr) 2020-04-22 2022-04-08 H4 Orphan Pharma Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales.
FR3111071B1 (fr) * 2020-06-04 2023-01-13 H4 Orphan Pharma Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003023A1 (fr) * 1986-10-31 1988-05-05 Mitsubishi Chemical Industries Limited Composition de medicament contre les maladies du foie et procede de preparation
US8207188B2 (en) 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
EP2037916A4 (en) 2006-04-07 2011-09-14 Mike Nicolaou PURE TRITOQUALINE ISOMERS
EP2559434A3 (en) 2007-02-12 2013-05-29 Mike Nicolaou Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist
US20110288114A1 (en) 2008-06-20 2011-11-24 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions

Also Published As

Publication number Publication date
HRP20160328T1 (hr) 2016-06-03
SI2844253T1 (sl) 2016-09-30
IL235358A0 (en) 2014-12-31
SMT201600102B (it) 2016-07-01
CA2871815A1 (en) 2013-11-07
US9301955B2 (en) 2016-04-05
EP2659890A1 (en) 2013-11-06
DK2844253T3 (en) 2016-04-18
EP2844253A1 (en) 2015-03-11
CY1117620T1 (el) 2017-04-26
CA2871815C (en) 2019-12-24
HUE027353T2 (en) 2016-09-28
EP2844253B1 (en) 2016-03-23
ES2569391T3 (es) 2016-05-10
US20150133487A1 (en) 2015-05-14
RS54733B1 (sr) 2016-10-31
IL235358B (en) 2019-09-26
WO2013164204A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
EP2968285A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
IL235358B (en) Tritocholine for use in the treatment of cystic fibrosis
GB201120993D0 (en) Novel compounds and their use in therapy
IL260115A (en) Methods for treating fibrosis (Leifat)
ZA201305276B (en) Novel composition for the treatment of cystic fibrosis
GB201118704D0 (en) Cystic fibrosis treatment
EP2922536A4 (en) USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
IL227732A0 (en) cosmetic use
GB2497886B (en) Hair treatment methods
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
PL2875026T3 (pl) Pochodne imidazopirydyny stosowane w leczeniu cukrzycy
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
IL244829A0 (en) Use of odipersil to treat mucopolysaccharidosis
GB2500999B (en) Hair treatment methods
GB201000499D0 (en) Treatment of cystic fibrosis
GB201311713D0 (en) Cystic fibrosis treatment
AU2012900572A0 (en) Compositions and methods for the treatment of cystic fibrosis
ZA201505093B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
PT2811993T (pt) Métodos de tratamento da fibrose
AU2012905072A0 (en) The use of bucillamine in the treatment of gout
EP2910232A4 (en) MASSAGE APPARATUS
GB201000571D0 (en) Treatment of cystic fibrosis
TWM433199U (en) Massage apparatus
GB201212604D0 (en) New treatment